

SUBJECT INDEX TO VOLUME 1

ABC-transporters	292	Blindness	91
expression of	294	β -Blockers	132
mechanisms of action of	292	in cardiac septic shock	132
structures of	292	Brain	188
Acute illness	128	actions of acetylcholine in	188
intranasal benzodiazepins for	128	behavior in	189
intranasal diamorphine for	129	cholinergic neurons in	189
intranasal fentanyl for	128	cognition in	189
intranasal ketamine for	129	Brain trauma	199
Albumin	319	Bronchial asthma	257
antioxidant activity of	320	drug targeting in	257
colloidal/pharmacological activity of	319	inhaled corticosteroids in	257
in clinical fluid management	319	Calcimimetics	147
in hypoalbuminemia	323	benefit of	147
in inflammation	320	role in altered mineral metabolism	151
in liver disease	321	role in secondary hyperparathyroidism	151
in microcirculation	320	Canines	107
in surgery	323	treatment of AGE-related cataracts in	107
mechanisms of action of	320	Carbapenem	177
safety of	325	for extended spectrum β -lactamase- producing infections	177
Analgesic drugs	276	Carnosine	101
Angiotensin receptor blockers	9	Cataracts	91
cerebrovascular protection with	9,10	intraocularly released L-carnosine on prevention/reversal of cataracts	111
in endothelial function	13	lipid peroxidation in	93
life trial of	11	Cataract surgery	92
MOSES trial of	11	complications of	92
risk of stroke by	9	Cerebral white matter lesions	9
SCOPE study of	11	pathogenesis of	9
value trial of	11	relation to arteriosclerosis/stroke	9
Angiotensin-1-receptor blocker (ARB)	47	Cerebrovascular protection	12
in cardiorenal disease	47	mechanisms of	12
in left ventricular hypertrophy	50	with angiotensin II/AT-2 receptor	13
in new-onset atrial fibrillation	52	with left ventricular mass regression	12
in new-onset diabetes	51	with vascular remodeling	13
in stroke	49	Cervical artery dissection	253
in systolic/diastolic heart failure	50	Cholinergic system	187
Anti-microbial therapies	175	functional anatomy of	187
Antipsychotic drugs	241	role in behavior	191
effect on cerebrovascular morbidity/ mortality	241	role in initiative	190
Antithrombotic agents	249	role in memory	190
Anti-TNF-alpha	313	role in sleep	190
efficacy in AS	313	role in vigilance	190
efficacy in PSA	313	Chronic pain signaling	274
in off-label rheumatic diseases	313	anatomy/physiology of	274
side effects of	314	combination therapies for relief of	278
Atrial fibrillation	251		
Atypical antipsychotics	5		
diabetes mellitus by	5		
dyslipidemia by	5		
hyperglycemia by	5		

Cinacalcet	151	Fluoroquinolones	117
clinical implications for use of	152	antimicrobial activity of	118
in treatment of SHPT	151	in bacterial meningitis	121
Coagulation disorders	253	in complicated urinary tract infections	121
Cochlear implants	231	in cystic fibrosis	118
benefits of	233	in gastrointestinal infections	120
bilateral implantation for	236	in infections	121
candidacy of	232	in otitis media	121
design/functioning mode of	235	in pediatrics	117
perimodiolar electrodes for	236	safety in children	122
short electrodes for	236	Gout	222
speech perception results in adults	233	febuxostat in	225
speech perception results in children	234	fenofibrate in	224
technological advances in	235	losartan in	223
Cyclophosphamide	55	sevelamer in	225
absorption of	56	treatment recommendations for	227
antitumor activity of	66	treatment strategies for hyperuricemia in	222
clinical pharmacokinetics of	56	Hypercalcemia	150
clinical pharmacology of	55	cardiovascular risk in	150
distribution of	56	Hyperphosphatemia	150
excretion of	61	cardiovascular risk in	150
mechanism of action of	66	Hypertension	263
metabolism of	57	causes of treatment resistance of	266
pharmacodynamics of	66	diastolic type	264
pharmacokinetic drug interactions of	65	guidelines for	263
pharmacokinetic parameters/modeling of	61	low-renin type	267
pharmacokinetic-pharmacodynamic		multicenter studies of	264
relationship of	69	systolic type	264
pharmacokinetic variability of	62	treatment resistance in	263
resistance phenomena of	69	Hyperuricemia	221
stereochemistry of	65	febuxostat in	225
toxicity of	68	fenofibrate in	224
transport of	56	in patients with gout	221
Enantiomeric local anesthetics	85	losartan in	223
clinical applications of	86	sevelamer in	225
epidural administration of	86	therapeutic agents for	221
experimental evaluation of safety of	85	treatment recommendations for	227
intrathecal administration of	87	Hypoalbuminemia	323
peripheral nerve blocks by	87	Ifosfamide	55
End-stage renal disease (ESRD)	147	absorption of	56
role of parathyroid hormone in		antitumor activity of	66
cardiovascular disease	148	clinical pharmacokinetics of	56
vascular calcification in	149	clinical pharmacology of	55
Epileptogenesis	302	distribution of	56
for P-glycoprotein in	302	excretion of	61
Extended-spectrum β -lactamase	173	mechanism of action of	66
classification of	173	metabolism of	57
clinical studies of	175	pharmacodynamics of	66
encoded by transmissible plasmids	174	pharmacokinetic drug interactions of	65
epidemiology of	174	pharmacokinetic parameters/modeling of	61
evolution of	173	pharmacokinetic-pharmacodynamic	
producing enterobacteriaceae	173	relationship of	69
treatment of infections caused by	173	pharmacokinetic variability of	62
Febrile neutropenia	119		

high velocity transdermal powdered drug		dopamine hypothesis for	2
delivery for	286	etiology of	2
in children	283	historical perspective of	1
laser assisted topical anesthetic delivery for	288	pharmacotherapy of	1,3
sonophoresis in	285	receptors in	3
topical anesthetics for	283	serotonin hypothesis for	3
Progesterone	211	treatment of	3
efficacy of	211	use of atypical antipsychotics	3
in preterm labour	215	Secondary hyperparathyroidism	147
in recurrent miscarriage	215	calcium-sensing receptors in	147
in threatened miscarriage	215	clinical consequences of	148
intramuscular route of	214	effect on cardiovascular mortality	147
intrauterine route of	213	effect on vascular calcification	147
oral route of	213	pathogenesis of	147
pharmacology of	212	Sepsis	131
rectal route of	212	in heart	131
routes of administration of	211,212	Septic cardiac shock	131
sublingual route of	213	beta-blocker therapy for	131
transdermic route of	212	Soy isoflavones	31
transnasal route of	213	adverse effects of	34
use in clinical practice	211	body composition in	33
vaginal route of	214	cancer risk/benefit of	33
Recombinant tissue-type plasminogen activator		cardiovascular effects of	32
(alteplase)	135	clinical evidence of	32
clinical trials for	137	in osteoporosis	33
drug interactions of	137	in postmenopausal women	31
efficacy in acute ischemic stroke	137	in vaginal atrophy	32
efficacy of	135	vasomotor symptoms of	32
efficacy/safety of combined intravenous/ intra-arterial thrombolysis with	143	Statins	157
efficacy/safety of thrombolysis with	143	effect on components of coagulation system	161
factors affecting safety of	141	effect on C-reactive protein	160
in acute ischemic stroke	143	effect on proliferation/apoptosis of vascular smooth muscle cells (VSMC)	161
in acute posterior circulation ischemic stroke	143	effects on bone formation	163
management of acute ischemic stroke by	135	effects on cardiovascular events	163
mechanism of action of	136	effects on endothelium	162
pharmacoeconomic aspects of	135,141	effects on immune mechanisms	162
pharmacokinetics of	136	efficacy in lowering LDL cholesterol	157
pharmacological properties of	135	in proteinuria	162
safety in acute ischemic stroke	140	lowering LDL cholesterol by	158
safety of	135	non-lipid effects of	160
Refractory epilepsy	294	pharmacokinetic properties of	165
nimodipine in	301	pleiotropic effects of	163
persistent plasmatic low levels in	299	safety/tolerability of	167
real-time pharmacokinetics studies in	300	Stroke	250
Rheumatic diseases	311	primary prevention of	250
adalimumab for	312	Supraventricular arrhythmias	12
anti-TNF-alpha treatment in	311	Topiceuticals	273
efficacy in	312	compounded topical drugs as	276
etanercept for	312	in treatment of chronic pain	273
infliximab for	311,312	lidocaine patch 5% as	277
Ropivacaine	85	menthol-containing products as	276
clinical applications of	86	topical capsaicin as	277
epidural administration of	86	topical nonsteroidal anti-inflammatory drugs (topical NSAIDs) as	278
intrathecal administration of	87	use of	273
peripheral nerve blocks by	87	Schizophrenia	1
Schizophrenia	1	biochemical basis of	2

Traumatic brain injury	187	in laboratory animals	191
acetylcholinesterase inhibitors for	194	rehabilitation in	200
cholinergic mechanisms of	199	role of apolipoprotein E	198
cholinergic modulation in	200	role of cholinergic system	191
cholinergic treatment of	187,194,195	sleep/inflammation in	199
clinical response in	197	studies in acute	201
demographic variables of	199	studies in chronic	200
duration of treatment in	198		
effect of addiction	198	Vascular calcification	149
effect of brain maturation/aging	199	role of phosphorus/calcium in	149
genetics of	199		
human studies of	193		